The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
now ORPH
Suckers... Aim Market Makers are Judges,Jury and Executioners..
They raised the cash at 5.60..Why didn't they put a contingency plan in place to absorb the initial selling? The seed investors could be down almost 20% in 1 day.
Sorry they sold the 42 mil but still have 30 mil and change from the debt conversion. 'Separate to this conversion, the Company has been advised that Venn Life Sciences Holdings plc ("Venn") has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the Debt Conversion Shares, Venn will hold 30,071,428 ordinary shares, representing 3.18% of the enlarged issued share capital . Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumen's broker so as to ensure an orderly market in the ordinary shares.'
is worth 1 million as well.
£5m Market Cap with New Shares FYI
40 million shares of SKIN as well?
Cash £4.5m mcap £3.3m. Successful rto. I'll bite.
New Venn Life owners target €50m in revenue by 2022 Michael Cogley 12 May 2019 6:00 PM Cathal Friel will be the new CEO The new owners of listed clinical trials firm Venn Life Sciences intend to grow its revenue from €15m a year to €50m within the next three years, it is understood. Pharma services business Open Orphan performed a reverse takeover of Venn Life last Friday. The move was driven by Cathal Friel, formerly of Fastnet Oil & Gas and Amryt Pharma. Shareholders are expected to vote to approve the takeover in June, as well as a name change to Open Orphan PLC. The company has also begun raising funds to recapitalise the Venn Life business, which issued a profit warning alongside its 2018 results. It is believed the fundraise is being led by Arden Stockbrokers in London and by Tom Godfrey of IBI Corporate Finance. "The new entity intends on adding around €35m to the company's revenue over the next three years," according to a source familiar with the company. "That will be achieved through a number of acquisitions and deals, at which point the new owners will look to sell the business to a bigger player." Shares in Venn Life were suspended on the London AIM market last Friday morning as the company announced the merger. The transaction will see Venn issue new shares to meet the £5.7m valuation of Open Orphan, which will be issued to Open Orphan's shareholders. Friel will take over as the new chief executive while Tony Richardson, the company's current CEO, will assume the role of corporate development director are the new entity. Venn Life also published its annual results on Friday, which showed a loss of €1.06m as well as a slide in revenues, down to €14.6m from €17.8m a year earlier. Directors of the group expect there should be an increase in revenues and profitability in the coming months.
Open Orphan valued at €6.6 mil. Amazing! No clients,No revenue, Nada
I predicted this in December 15 Dec '18 Price: 1.75 Bronxville 943 posts RE: Open Orphan Are they planning a reverse merger? Any opinions? No Opinion
Cathal Friel new CEO https://irpages2.equitystory.com/websites/rns_news/English/1100/news-tool---rns---eqs-group.html?article=29017038&company=vennlife
Venn sold 42 million shares for €575k.
To £600,000 for VENN..
The group all here ramping away even though they know it has probably already peaked. All ready, as a group.
this morning... Anyone know if VENN has any other incubator investments?
as people cotton onto the fact that a rerate is due
will rise soon enough imo
Mrcalm, try “calming” down on the ramps It’s not helping and the price is falling as is skin
its a breather before next leg up to 4p
the skin guys will be here soon enough with our £2m mcap
can buy for 3.29